Debt-to-equity of Janux Therapeutics, Inc. from 31 Mar 2022 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Janux Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 31 Dec 2025.
  • Janux Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 4.4%, a 9.1% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Janux Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 4.4% -0.44% -9.1% 31 Dec 2025
Q3 2025 4.2% -2% -32% 30 Sep 2025
Q2 2025 4.3% -2.7% -39% 30 Jun 2025
Q1 2025 4.5% -4.6% -51% 31 Mar 2025
Q4 2024 4.8% -7.3% -60% 31 Dec 2024
Q3 2024 6.1% -6.7% -52% 30 Sep 2024
Q2 2024 7% -6.5% -48% 30 Jun 2024
Q1 2024 9% -4% -31% 31 Mar 2024
Q4 2023 12% +1.6% +15% 31 Dec 2023
Q3 2023 13% +4.9% +61% 30 Sep 2023
Q2 2023 14% +7.9% +139% 30 Jun 2023
Q1 2023 13% +9.5% +270% 31 Mar 2023
Q4 2022 10% 31 Dec 2022
Q3 2022 8% 30 Sep 2022
Q2 2022 5.7% 30 Jun 2022
Q1 2022 3.5% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.